Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis
Ibrutinib is a novel drug used in haematological malignancies. Its use is associated with an increased risk of atrial fibrillation (AF), which, in turn, exposes patients to embolic risk, including stroke. Reducing this risk requires anticoagulant therapy which is a matter of concern in the context o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2021-09-01
|
| Series: | Romanian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/rjim-2021-0015 |